OncoMatch/Clinical Trials/NCT04183712
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Is NCT04183712 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including gemcitabine and oxaliplatin. and Afatinib for gallbladder carcinoma.
Treatment: gemcitabine and oxaliplatin. · Afatinib — The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Biomarker criteria
Required: HER2 (ERBB2) mutation
harboring mutations or abnormal activation of erb-b2 receptor tyrosine kinase signal pathway components
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: molecular target therapy
Anti-tumor molecular target therapy
Cannot have received: chemotherapy
Exception: chemotherapy in 6 months
anti-tumor chemotherapy in 6 months
Cannot have received: radiation therapy
lesions have been treated by irradiation
Cannot have received: other clinical trial therapy
participate in other therapeutic or interventional clinical trials
Lab requirements
Blood counts
white blood cells≥3×10^9/L, neutrophils≥1.5×10^9/L, platelets≥75×10^9/L , hemoglobin ≥ 90g/L
Kidney function
creatinine clearance rate≥60ml/min
Liver function
ALT≤5×upper limit of normal (ULN), AST≤5×ULN, the Child-Pugh classification for class A or B
Adequate hepatic, hematologic and renal functions(ALT≤5×upper limit of normal (ULN), AST≤5×ULN, the Child-Pugh classification for class A or B, white blood cells≥3×10^9/L, neutrophils≥1.5×10^9/L, platelets≥75×10^9/L , hemoglobin ≥ 90g/L, creatinine clearance rate≥60ml/min;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04183712 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify